Caselitz M, Link H, Hein R, Maschek H, Böker K, Poliwoda H, Manns M P
Dept. of Gastroenterology and Hepatology, Medical School of Hannover, Germany.
J Hepatol. 1997 Sep;27(3):572-7. doi: 10.1016/s0168-8278(97)80363-7.
Several cases have been reported showing clearance of HBsAg in chronic hepatitis B carriers due to adoptive transfer of immunity by an hepatitis B immunised bone marrow.
We report on a 27-year-old man with chronic myelocytic leukemia and asymptomatic chronic hepatitis B who received allogeneic bone marrow transplantation (BMT). The donor was his HLA identical brother with natural immunity against hepatitis B. Before BMT the donor had received an additional dose of recombinant hepatitis B vaccine. Twenty days after BMT alanine aminotransferase levels increased and graft versus host disease of the skin was observed. Elevation of liver enzymes was initially attributed to graft versus host disease of the liver and the patient received high doses of steroids in addition to standard immunosuppression. Alanine aminotransferase levels increased up to a maximum on day 52 while the HBV DNA level peaked on day 38 after BMT. A liver biopsy showed reactivation of hepatitis B and treatment with steroids was tapered down. Although alanine aminotransferase and HBV DNA levels decreased, liver function deteriorated. The patient died 130 days after BMT due to liver failure.
This report indicates that disturbance of the balance between HBV replication and immune control after BMT may result in fatal reactivation of hepatitis B. Careful monitoring, including HBV DNA level and early liver biopsy, of patients with chronic hepatitis B undergoing BMT as well as determination of the HBV immune status of the BMT donor is suggested and necessary.
已有数例报告显示,慢性乙型肝炎携带者因接种乙肝疫苗的骨髓进行免疫过继转移而出现乙肝表面抗原清除。
我们报告一名27岁患有慢性粒细胞白血病和无症状慢性乙型肝炎的男性接受了异基因骨髓移植(BMT)。供体是他的 HLA 相同的哥哥,对乙肝具有天然免疫力。在进行BMT之前,供体额外接种了一剂重组乙肝疫苗。BMT后20天,丙氨酸转氨酶水平升高,并观察到皮肤移植物抗宿主病。肝酶升高最初归因于肝脏移植物抗宿主病,除了标准免疫抑制外,患者还接受了高剂量的类固醇治疗。丙氨酸转氨酶水平在第52天达到最高,而HBV DNA水平在BMT后第38天达到峰值。肝脏活检显示乙肝再激活,类固醇治疗逐渐减量。尽管丙氨酸转氨酶和HBV DNA水平下降,但肝功能仍恶化。患者在BMT后130天因肝衰竭死亡。
本报告表明,BMT后HBV复制与免疫控制之间的平衡紊乱可能导致乙肝致命性再激活。建议并需要对接受BMT的慢性乙型肝炎患者进行仔细监测,包括HBV DNA水平和早期肝脏活检,以及确定BMT供体的HBV免疫状态。